Примери за използване на Maximum recommended human dose на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
the human values at the maximum recommended human dose).
respectively, the human values at the maximum recommended human dose[MRHD]).
a reproductive and developmental toxicity study in cynomolgus monkeys at doses of up to 50 mg/kg/week(producing exposures of about 70 times the clinical exposure at maximum recommended human dose[MRHD]).
in rats after 104 weeks at 20 to 60 mg/kg/day(3 to 10 times the mean steady-state AUC at the maximum recommended human dose) and increased adrenocortical carcinomas and combined adrenocortical adenomas/carcinomas in female rats at 60 mg/kg/day(10 times the mean steady-state AUC at the maximum recommended human dose).
in rats after 104 weeks at 20 to 60 mg/ kg/ day(3 to 10 times the mean steady-state AUC at the maximum recommended human dose) and increased adrenocortical carcinomas and combined adrenocortical adenomas/ carcinomas in female rats at 60 mg/ kg/ day(10 times the mean steady-state AUC at the maximum recommended human dose).
in rats after 104 weeks at 20 to 60 mg/kg/day(3 to 10 times the mean steady-state AUC at the maximum recommended human dose) and increased adrenocortical carcinomas and combined adrenocortical adenomas/carcinomas in female rats at 60 mg/kg/day(10 times the mean steady-state AUC at the maximum recommended human dose).
were reported at all dose levels; pup exposures at the lowest dose tested were≥ 15 times the maximum recommended human dose.
No effects on male or female fertility and reproductive performance indices were observed at≤ 100 mg/kg/day(yielding exposures approximately 8 and 5 times, respectively, those obtained with the maximum recommended human dose of the ivacaftor component of Orkambi based on summed AUCs of ivacaftor and its metabolites extrapolated from Day 90 exposures at 100 mg/kg/day in the 6-month repeat-dose toxicity study and gestation Day 17 exposures in the embryofoetal development study in this species).
respectively, those obtained with the maximum recommended human dose of the ivacaftor component of Orkambi based on summed AUCs of ivacaftor
and/or parenchymal cell loss) in rats after 104 weeks at 20 mg/kg/day to 60 mg/kg/day(3 to 10 times the mean steady-state AUC at the maximum recommended human dose) and increased adrenocortical carcinomas and combined adrenocortical adenomas/carcinomas in female rats at 60 mg/kg/day(10 times the mean steady-state AUC at the maximum recommended human dose).
These doses represent 2 and 1 times, respectively, the maximum recommended human dose.
The dose of 150 mg/ kg approximately corresponds to the maximum recommended human dose.
Pup exposures at the lowest dose tested were≥ 15 times the maximum recommended human dose.
no evidence of teratogenic potential at systemic exposures equivalent to the maximum recommended human dose.
These doses in marmoset, respectively, represent 0.3 and 1.2-times the maximum recommended human dose(MRHD) of valsartan
These doses in rat, respectively, represent 18 and 73 times the maximum recommended human dose(MRHD) of valsartan
There was no evidence of embryofoetal toxicity in rabbits at 3 times the maximum recommended human dose(MRHD) of 60 mg based on body surface area.
No adverse effects were observed in a fertility study in female rats at doses up to 22 times the maximum recommended human dose on a mg/m basis.
the clinical exposure at the Maximum Recommended Human Dose(MRHD) and caused reversible renal tubular dilation.
The foetal effects in mice administered the surrogate antibody occurred at exposures less than the AUC exposure at the maximum recommended human dose of 15 mg/kg olaratumab.